Stay updated on Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel
Sign up to get notified when there's something new on the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page.

Latest updates to the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page
- Check2 days agoChange DetectedThe ClinicalTrials.gov website revision updated from v3.8.0 to v3.8.1, with no change to the clinical study record.SummaryDifference0.0%

- Check9 days agoChange DetectedThe record presents details of Pfizer’s completed Phase 3 comparison of PF-05280014 and EU-sourced trastuzumab, both combined with paclitaxel, for HER2-positive metastatic breast cancer. It also includes study locations, outcome measures, publications, and information about requesting de-identified participant data.SummaryDifference100%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe study record remains on a 403 Forbidden error page, with no visible changes to the page.SummaryDifference0.2%

- Check30 days agoChange DetectedA notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows a 403 Forbidden error with a minimal header and a Home link, replacing the previously available study details and related navigation.SummaryDifference17%

Stay in the know with updates to Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel
Enter your email address, and we'll notify you when there's something new on the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page.